BioSpace News Archive

Genialis, the RNA-biomarker company, announced a new partnership with the Pancreatic Cancer Action Network to expand the validation of the Genialis™ krasID biomarker in the pancreatic cancer histology.

Medicenna Therapeutics Corp. announced that comprehensive clinical results from the monotherapy dose escalation portion of the Phase 1/2 ABILITY-1 study evaluating MDNA11, in patients with advanced solid tumors, will be presented today at the 10th Annual Oncology Innovation Forum being held in Chicago.

The Alexander Shulgin Research Institute has unveiled a groundbreaking discovery in the journal Molecular Pharmacology: the first bifunctional compound that acts as both a 5-HT2A receptor antagonist and a voltage-gated sodium channel blocker.

OPKO Health, Inc. announced that management will be participating in the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City.

Valneva SE announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending authorization of Valneva’s single-dose vaccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older.

Takeda announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval, under exceptional circumstances, of recombinant ADAMTS13 for the treatment of ADAMTS13 deficiency in children and adult patients with cTTP.

AB Science SA is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in the treatment of amyotrophic lateral sclerosis.

Bavarian Nordic A/S announced the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration seeking approval of a freeze-dried formulation of JYNNEOS® for prevention of smallpox and mpox disease in adults 18 years of age and older.

Florida Cancer Specialists & Research Institute, LLC is pleased to welcome hematologist and medical oncologist Juan Garza, MD to the statewide practice.

AstraZeneca is pleased to announce that Truqap™ in combination with fulvestrant is now available in Canada for the treatment of adult female patients with hormone receptor -positive, human epidermal growth factor receptor 2 -negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1 or PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.